Etrafon-A

• Antipsychotics
• Phenothiazines
• Dopamine Antagonists
• ATC:N05AB03

• Apo-Perphenazine
• Chlorperphenazine
• Decentan
• Emesinal
• Etaperazin
• Etaperazine
• Ethaperazine
• Etrafon-A
• Etrafon-Forte
• F-Mon
• Fentazin
• Fluphenazine
• PZC
• Perfenazina
• Perfenazine
• Perphenan
• Perphenazin
• Perphenazine and Amitriptyline Hcl
• Pms Perphenazine
• Thilatazin
• Tranquisan
• Trifaron
• Trilafon
• Trilafon Concentrate
• Trilifan
• Triphenot

• Apo Peram Tab 2-25 (Amitriptyline Hydrochloride + Perphenazine)
• Apo Peram Tab 3-15 (Amitriptyline Hydrochloride + Perphenazine)
• Elavil Plus Tab (Amitriptyline Hydrochloride + Perphenazine)
• Etrafon 2 10 (Amitriptyline Hydrochloride + Perphenazine)
• Etrafon a Tab (Amitriptyline Hydrochloride + Perphenazine)
• Etrafon D Tab (Amitriptyline Hydrochloride + Perphenazine)
• Etrafon F Tab (Amitriptyline Hydrochloride + Perphenazine)
• Pms-Levazine 2/25 Tab (Amitriptyline Hydrochloride + Perphenazine)
• Pms-Levazine 3/15 Tab (Amitriptyline Hydrochloride + Perphenazine)
• Pms-Levazine 4/25 Tab (Amitriptyline Hydrochloride + Perphenazine)
• Proavil Tab (Amitriptyline Hydrochloride + Perphenazine)
• Triavil Tab (Amitriptyline Hydrochloride + Perphenazine)

C₂₁H₂₆ClN₃OS

http://www.rxlist.com/cgi/generic3/perphenazine.htm

Etrafon-A FDA

Etrafon-A MSDS

Cusic, U.S. pat. 2860138

403.969 g/mol

97 ^oC

28.3 mg/L

Solid

4.176

Liquid; Solution; Syrup; Tablet (2, 4, 8, or 16 mg)

For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.

Perphenazine is a piperazinyl phenothiazine, acts on the central nervous system, and has a greater behavioral potency than other phenothiazine derivatives whose side chains do not contain a piperazine moiety. It is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Perphenazine is 10 to 15 times as potent as chlorpromazine; that means perphenazine is a highly potent antipsychotic. In equivalent doses it has approximately the same frequency and severity of early and late extrapypramidal side-effects compared to Haloperidol.

Absolute bioavailability is 40% following oral administration.

Symptoms of overdose include stupor or coma, and children may have convulsive seizures. Signs of arousal may not occur for 48 hours. Oral LD₅₀=318 mg/kg (rat); IPR LD₅₀=64 mg/kg (mouse)

This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Given the likelihood that a substantial proportion of patients exposed chronically to neuroleptics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.

Humans and other mammals